RSLS
Income statement / Annual
Last year (2024), ReShape Lifesciences Inc.'s total revenue was $8.01 M,
a decrease of 7.74% from the previous year.
In 2024, ReShape Lifesciences Inc.'s net income was -$7.13 M.
See ReShape Lifesciences Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$8.01 M |
$8.68 M |
$11.24 M |
$13.60 M |
$11.30 M |
$15.09 M |
$606.71 K |
$1.29 M |
$786.66 K |
$292.00 K |
| Cost of Revenue |
$2.95 M
|
$3.13 M
|
$4.44 M
|
$5.25 M
|
$5.04 M
|
$5.78 M
|
$164.30 K
|
$936.39 K
|
$431.48 K
|
$125.00 K
|
| Gross Profit |
$5.06 M
|
$5.55 M
|
$6.80 M
|
$8.35 M
|
$6.26 M
|
$9.31 M
|
$442.41 K
|
$350.77 K
|
$355.18 K
|
$167.00 K
|
| Gross Profit Ratio |
0.63
|
0.64
|
0.61
|
0.61
|
0.55
|
0.62
|
0.73
|
0.27
|
0.45
|
0.57
|
| Research and Development Expenses |
$1.80 M
|
$2.32 M
|
$2.54 M
|
$2.52 M
|
$3.50 M
|
$3.12 M
|
$5.72 M
|
$5.78 M
|
$5.17 M
|
$8.14 M
|
| General & Administrative Expenses |
$6.93 M
|
$10.32 M
|
$17.25 M
|
$24.41 M
|
$10.53 M
|
$17.22 M
|
$14.03 M
|
$25.98 M
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$2.99 M
|
$7.55 M
|
$14.09 M
|
$8.89 M
|
$4.69 M
|
$4.85 M
|
$5.24 M
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$9.92 M
|
$17.87 M
|
$31.34 M
|
$33.58 M
|
$15.22 M
|
$22.07 M
|
$19.26 M
|
$25.98 M
|
$17.98 M
|
$19.89 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$10.64 K
|
-$652.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$11.73 M
|
$20.19 M
|
$33.88 M
|
$36.10 M
|
$18.72 M
|
$25.19 M
|
$24.98 M
|
$31.76 M
|
$23.15 M
|
$28.03 M
|
| Cost And Expenses |
$15.73 M
|
$23.32 M
|
$57.59 M
|
$71.48 M
|
$23.76 M
|
$30.98 M
|
$25.15 M
|
$32.70 M
|
$23.58 M
|
$28.16 M
|
| Interest Income |
$14.00 K
|
$26.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.07 K
|
$5.84 K
|
$1.82 K
|
| Interest Expense |
$0.00
|
$0.00
|
$113.00 K
|
$832.00 K
|
$2.05 M
|
$451.00 K
|
$12.00 K
|
$3.87 K
|
$4.10 M
|
$939.18 K
|
| Depreciation & Amortization |
$22.00 K
|
$154.00 K
|
$2.15 M
|
$1.97 M
|
$1.67 M
|
$894.00 K
|
$581.00 K
|
$330.00 K
|
$192.00 K
|
$188.61 K
|
| EBITDA |
-$6.65 M |
-$14.49 M |
-$24.93 M |
-$60.62 M |
-$18.10 M |
-$17.22 M |
-$36.97 M |
-$34.39 M |
-$19.51 M |
-$27.68 M |
| EBITDA Ratio |
-0.83
|
-1.67
|
-2.22
|
-4.46
|
-1.6
|
-1.14
|
-60.93
|
-26.72
|
-24.79
|
-94.79
|
| Operating Income Ratio |
-0.83
|
-1.69
|
-2.41
|
-1.83
|
-1.1
|
-1.05
|
-63.53
|
-24.4
|
-28.98
|
-95.43
|
| Total Other Income/Expenses Net |
$637.00 K
|
$4.05 M
|
-$19.52 M
|
-$38.49 M
|
-$9.35 M
|
-$50.64 M
|
-$167.73 K
|
-$1.37 M
|
-$565.22 K
|
$2.37 M
|
| Income Before Tax |
-$7.09 M
|
-$11.34 M
|
-$46.59 M
|
-$63.42 M
|
-$21.81 M
|
-$75.10 M
|
-$38.71 M
|
-$36.13 M
|
-$23.36 M
|
-$25.50 M
|
| Income Before Tax Ratio |
-0.89
|
-1.31
|
-4.15
|
-4.66
|
-1.93
|
-4.98
|
-63.81
|
-28.07
|
-29.7
|
-87.33
|
| Income Tax Expense |
$39.00 K
|
$52.00 K
|
-$380.00 K
|
-$274.00 K
|
-$181.00 K
|
-$893.00 K
|
-$3.45 M
|
-$2.31 M
|
$0.00
|
-$2.56 M
|
| Net Income |
-$7.13 M
|
-$11.39 M
|
-$46.21 M
|
-$63.15 M
|
-$21.63 M
|
-$74.21 M
|
-$81.15 M
|
-$33.82 M
|
-$23.36 M
|
-$25.50 M
|
| Net Income Ratio |
-0.89
|
-1.31
|
-4.11
|
-4.64
|
-1.91
|
-4.92
|
-133.76
|
-26.27
|
-29.7
|
-87.33
|
| EPS |
-345.74 |
-2771.94 |
-157897 |
-419004 |
-503023.26 |
-1094068 |
-4270786 |
-4524000 |
-10548750 |
-2025708 |
| EPS Diluted |
-345.74 |
-2771.94 |
-157897 |
-419004 |
-503023.26 |
-1094068 |
-4270786 |
-4524000 |
-10548750 |
-2025708 |
| Weighted Average Shares Out |
$20.62 K
|
$4.11 K
|
$292.68
|
$150.70
|
$43.00
|
$21.64
|
$8.75
|
$7.69
|
$0.00
|
$7.68
|
| Weighted Average Shares Out Diluted |
$20.62 K
|
$4.11 K
|
$292.68
|
$150.70
|
$43.00
|
$21.64
|
$8.75
|
$7.69
|
$0.00
|
$7.68
|
| Link |
|
|
|
|
|
|
|
|
|
|
